Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurologic manifestations of COVID-19 in a Diverse Population in Chicago, Illinois
Infectious Disease
Infectious Disease Posters (7:00 AM-5:00 PM)
002
NA
We aimed to further characterize the neurologic manifestations observed in patients hospitalized with Coronavirus disease 2019 (COVID-19), particularly ischemic stroke in a diverse population.
We retrospectively reviewed data records of 50 patients with COVID-19 (48% African American and 24% Latino) who were evaluated by the neurology services in 2020. Patients were categorized into 2 groups based on timing of developing neurological manifestations: the “Neuro first” group had neurological manifestations upon initial assessment, and the “COVID first” group developed neurological symptoms greater than 24 hours after hospitalization. The demographics, comorbidities, disease severity and neurological symptoms of both groups were analyzed. Statistical analysis was performed to compare the two groups. We further analyzed acute ischemic stroke patients by comparing with historic patients with AIS without COVID-19 admitted in the same time frame in 2019 and 2020.
Most common neurological manifestations observed were encephalopathy (n = 30), cerebrovascular disease (n = 20), cognitive impairment (n = 13), seizures (n = 13), hypoxic brain injury (n = 7), dysgeusia (n = 5), and extraocular movement abnormalities (n = 5). The “COVID-19 first” group had more severe/critical disease course (83.3% vs 53.8%, p 0.025). Out of 13 patients with AIS and COVID-19, Latinos and African Americans compromised the majority of our cohort (76.8%). Most strokes were cortical (84.6%) and more than 50% had no identifiable source. COVID-19 was associated with discharge to mRS>2 (p 0.046, OR 3.82, CI 1.02-14.3).
Neurologic manifestations of COVID-19 are highly variable and can occur prior to the diagnosis of or as a complication of the viral infection. The COVID-19 patients who developed neurologic symptoms later in hospitalization had more severe disease courses. We noted a high percentage of African American and Latino individuals in both groups. Concurrent AIS and COVID-19 was associated with worse outcomes.
Authors/Disclosures
Alejandro Vargas, MD, MS, FÂ鶹´«Ã½Ó³»­ (Rush University Medical Center)
PRESENTER 		Dr. Vargas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer U.S. LLC Pharmaceuticals.
Pranusha Pinna, DO Dr. Pinna has nothing to disclose.
Parneet K. Grewal, MD The institution of Dr. Grewal has received research support from Bristol Myer Squibb Foundation. The institution of Dr. Grewal has received research support from IPSEN Global.
Ivan Da Silva, MD Dr. Da Silva has nothing to disclose.
Julianne Hall, MD Dr. Hall has nothing to disclose.
Rima Dafer, MD (Rush University Medical Center) Dr. Dafer has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Dafer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Dafer has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Anderson, Rasor, and partners.